April 7, 2006European Heart Journal
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome
Why the study?
Does rosuvastatin 20 mg/day reduce pro-inflammatory cytokine production in patients with troponin-positive acute coronary syndrome?
Population
35 patients with troponin-positive acute coronary syndrome (ACS)
Comparison
Rosuvastatin 20 mg/day vs Placebo
Design
RCT, randomized
Follow-up
42 days
Authors
Discussion
Loading...
Member takes
Implication
Supports early statin use in ACS; confirms rapid immunomodulatory effects in RCT.
Structured PICO
Does rosuvastatin 20 mg/day reduce pro-inflammatory cytokine production in patients with troponin-positive acute coronary syndrome?
P
Population
35 patients with troponin-positive acute coronary syndrome (ACS)
I
Intervention
Rosuvastatin 20 mg/day
C
Comparator
Placebo
O
Outcome
Anti-inflammatory effects measured by lymphocyte intracellular cytokine production (TNF-alpha and IFN-gamma) and plasma concentrations at days 1, 3 (72 h), and 42surrogate
Rosuvastatin 20 mg/day exerts rapid immunomodulatory effects by reducing pro-inflammatory cytokines within 72 hours in patients with acute coronary syndrome.
Cite This Study
Link et al. (2006) studied this question.